Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03379441
Title Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Turin, Italy
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.